<DOC>
	<DOCNO>NCT00752895</DOCNO>
	<brief_summary>RATIONALE : American ginseng extract may prevent reduce acute respiratory illness patient chronic lymphocytic leukemia . It yet know whether American ginseng extract effective placebo prevent respiratory infection . PURPOSE : This randomized phase III trial study side effect American ginseng extract see well work compare placebo prevent respiratory infection reduce antibiotic use patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>American Ginseng Extract Preventing Respiratory Infection Reducing Antibiotic Use Patients With CLL</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess effect American ginseng extract number day acute respiratory infection ( ARI ) peak respiratory illness season ( January-March ) patient chronic lymphocytic leukemia ( CLL ) . - To determine safety American ginseng extract patient evaluate accord NCI CTCAE v3.0 . Secondary - To assess effect treatment antibiotic use day ( AUDs ) . - To assess effect treatment rate infection diagnose physician . - To assess effect treatment duration severity ARI episode . - To assess effect treatment major infection define infection severe enough require hospitalization intravenous antibiotic . - To assess effect treatment incidence herpes zoster infection define episode physician-diagnosed zoster infection . - To assess effect treatment CLL disease activity ( i.e. , serum IgG , total lymphocyte count , platelet count , Rai stag ) . - To determine incidence ARI type illness untreated cohort CLL patient entire winter respiratory illness season ( January 1- April 30 ) . Tertiary - To determine effect treatment incidence influenza respiratory syncytial virus confirm physician . OUTLINE : This multicenter study . Patients stratify accord antibiotic prophylaxis trimethoprim-sulfamethoxazole ( yes v ) , serum IgG ( ≤ 500 mg/dL v &gt; 500 mg/dL ) , influenza vaccine status ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral American ginseng extract twice daily . - Arm II : Patients receive oral placebo twice daily . Treatment arm continue 4 month absence illness adverse event . After completion study treatment , patient follow 4 week phone .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia ( CLL ) Phenotypic evidence ( i.e. , flow cytometry bone marrow biopsy ) disease Untreated CLL allow PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; 12 month Creatinine &lt; 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min AST/ALT ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN Not pregnant nursing Fertile patient must use effective contraception prior study treatment No know cirrhosis , collagen vascular disease , multiple sclerosis , HIV positivity No prior concurrent malignancy except nonmelanoma skin cancer carcinoma situ cervix Other prior malignancy allow provided patient diseasefree &gt; 5 year No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia No psychiatric social illness would limit compliance study requirement No history allergy adverse response ginseng product No history seasonal environmental allergy require ongoing treatment antihistamine , intranasal corticosteroid , systemic corticosteroid PRIOR CONCURRENT THERAPY : More 3 month since prior concurrent chlorambucil At least 1 month since prior concurrent herbal ginseng product No prior concurrent fludarabine , alemtuzumab , rituximab , intravenous immunoglobulin , hematopoietic stem cell transplantation No concurrent corticosteroid ( 20 mg/day prednisone equivalent ) No concurrent antibiotic prophylaxis , except trimethoprimsulfamethoxazole No concurrent warfarin No concurrent investigational commercial agent therapy intent treat patient 's malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>